An interventional study of controlled physical activity in Type 1 Diabetes, sponsored by University Hospital, Clermont-Ferrand. Completed at 1 site in France. Open to participants aged 6 Years to 12 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by University Hospital, Clermont-Ferrand · Not applicable, Interventional, and Prevention
Fel S, Rochette E, Walther G, Echaubard S, Pereira B, Merlin E, Terral D, Duche P. Maximal Fat Oxidation During Exercise Is Already Impaired in Pre-pubescent C…PubMed 33897473 ↗
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 271 studies in Diabetes Mellitus, Type 1 with a site in France — 39 open to participants now, 45 under way, 8 of them phase 3. Diabetes Mellitus, Type 1 · France.
Among the 271 studies in Diabetes Mellitus, Type 1 with a site in France, this one is the 117th largest by enrollment of the 193 interventional ones that give a count, is one of 11 that started in 2017, is one of 103 with no phase, and was the 137th registered.
3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →39 of the 271 studies in Diabetes Mellitus, Type 1 with a site in France are open now. Recruiting first, the newest first:
Insulet Corporation · Sites in France
Ages 2+
Sanofi · Sites in France, Belgium, Germany and 3 more countries
Tandem Diabetes Care, Inc. · Sites in France
Ages 6+
Eli Lilly and Company · Sites in France, United States, Australia and 17 more countries
Ages 1–35
Eli Lilly and Company · Sites in France, United States, Australia and 16 more countries
Ages 1–35
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.
This study: 6 Years to 12 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
271 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 25 · Phase 3 55 · Phase 4 7
First in 2000; this study’s year is marked. 11 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 48 is above the median of 40 across 2,824 interventional studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 67 across the 193 interventional studies, 153 across the 78 observational. Of the 205 that completed or were terminated, 48 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
90 of 271 have an industry lead sponsor. The 10 most frequent:
University Hospital, Clermont-Ferrand is the lead sponsor of 859 studies on the registry; 177 are open to participants now.
University Hospital, Clermont-Ferrand has 1 study filed under Diabetes Mellitus, Type 1 — fewer than ten, so there is no comparison to draw.
17 of the studies in Diabetes Mellitus, Type 1 with a site in France that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06914895Phase 3Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT06962280Phase 3Eli Lilly and CompanyA Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT04583462Phase 3Assistance Publique - Hôpitaux de ParisImpact of Metformin on Peripheral Arterial Calcification in Type 1 Diabetes | 2027-09-29 |
| NCT07457580SanofiReal-World Study of Patients With Type 1 Diabetes Treated With Teplizumab as Part of Managed Access Programs (MAPs) | 2026-11-30 |
| NCT05221359DefymedPilot Study Evaluating Safety of ExOlin® in Patients With Poorly Controlled Type 1 Diabetes | 2026-12 |
Add all 17 to your calendar (.ics) → With an account.
Among the 271 studies in Diabetes Mellitus, Type 1 with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The type 1 diabetes is a common chronic disease characterised by the stop of production of insulin by the pancreas. A lot of factors modify blood glucose. The objective is to study the effect of type 1 diabetes on the use of energy substrates (fats and carbohydrates) during exercise of increasing intensity by a comparison with non-diabetic controls children.
The type 1 diabetes is a common chronic disease characterised by the stop of production of insulin by the pancreas. A lot of factors modify blood glucose. The objective is to study the effect of type 1 diabetes on the use of energy substrates (fats and carbohydrates) during exercise of increasing intensity by a comparison with non-diabetic controls children.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Comparison between infants with type 1 diabetes and infants without type 1 diabetes during exercise :
Procedure: controlled physical activity
Comparison between infants with type 1 diabetes and infants without type 1 diabetes during exercise :
Procedure: controlled physical activity
Comparison between infants with type 1 diabetes and infants without type 1 diabetes during exercise :
Comparison of substrate utilization between infants with type 1 diabetes and infants without type 1 diabetes during exercise
Measurements will be carried out by indirect calorimetry and the relationship between CO2 et O2 (Metamax)
Time frame: at day 1
hormonal regulation of blood glucose
insulin, glucagon, adrenaline, cortisol and growth hormone will be metered according to their half life until 2 hours after physical activity (T12, T20, T40, T60, T120)
Time frame: at day 1
lipoxmax : the intensity for wich lipid oxydation is maximum will be carried out by indirect calorimetry
during exercise
Time frame: at day 1
Comparison between infants during 10 days before and 4 days after exercise of blood glucose modification
Comparison of curves of interstitial blood glucose measured with Freestyle®
Time frame: 10 days before and 4 days after exercise of blood glucose modification
Ran from Apr 2017 to primary completion in Apr 2018, 12 months.
Of 852 non-industry interventional studies with no phase under Diabetes Mellitus, Type 1, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 37. This study's 12 months is below that.
Counting every sponsor, half of 957 studies reached it within 18 months; a quarter within 9 and three quarters within 35.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 17, 2026: primary completion May 2019 → Apr 2018 and completion Dec 2019 → Nov 2018.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
Fel S, Rochette E, Walther G, Echaubard S, Pereira B, Merlin E, Terral D, Duche P. Maximal Fat Oxidation During Exercise Is Already Impaired in Pre-pubescent C…PubMed 33897473 ↗
Fel S, Rochette E, Walther G, Echaubard S, Pereira B, Merlin E, Terral D, Duche P. Maximal Fat Oxidation During Exercise Is Already Impaired in Pre-pubescent C…PubMed 33897473 ↗
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Clermont-Ferrand →